Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
暂无分享,去创建一个
P. Benfield | A Ward | D M Campoli-Richards | J P Monk | A Price | P Benfield | P A Todd | P. A. Todd | J. Monk | A. Ward | D. Campoli-Richards | A. Price | D. M. Campoli-Richards | A. H. Price
[1] P. Piot,et al. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae , 1984, Antimicrobial Agents and Chemotherapy.
[2] Scully Be,et al. Treatment of serious infections with intravenous ciprofloxacin. , 1987 .
[3] T. Bergan,et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. , 1986, Chemotherapy.
[4] D. Bouanchaud,et al. Comparative efficacy of pefloxacin and six other antimicrobial agents on Staphylococcus aureus experimental abscesses. , 1986, The Journal of antimicrobial chemotherapy.
[5] S. Eykyn,et al. TREATMENT OF MULTIRESISTANT SALMONELLA TYPHI WITH ORAL CIPROFLOXACIN , 1987, The Lancet.
[6] H. Zeiler. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin. , 1985, Drugs under experimental and clinical research.
[7] D. Gibson,et al. Studies on ciprofloxacin therapy of experimental Legionnaires' disease. , 1985, The Journal of infection.
[8] R. Eng,et al. The effect of ciprofloxacin on methicillin-resistant Staphylococcus aureus. , 1986, The Journal of antimicrobial chemotherapy.
[9] J. Kurz,et al. Isolation and structural elucidation of urinary metabolites of ciprofloxacin. , 1986, Arzneimittel-Forschung.
[10] D. Raoult,et al. Ciprofloxacin therapy for Mediterranean spotted fever , 1986, Antimicrobial Agents and Chemotherapy.
[11] H. Neu,et al. ORAL CIPROFLOXACIN THERAPY OF INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA , 1986, The Lancet.
[12] G. Drusano,et al. Dose ranging study and constant infusion evaluation of ciprofloxacin , 1986, Antimicrobial Agents and Chemotherapy.
[13] A. Espinel-Ingroff,et al. Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses , 1986, Antimicrobial Agents and Chemotherapy.
[14] C. Gaudreau,et al. Comparative in vitro activity of four quinolones and four other agents against enteropathogens , 1987 .
[15] H. Tanimura,et al. Transfer of ciprofloxacin to bile and determination of biliary metabolites in humans. , 1986, Arzneimittel-Forschung.
[16] W. Roszkowski,et al. The Effect of Subinhibitory Concentrations of selected Antibiotics on Bacteria-Phagocyte Interaction , 1985 .
[17] J. Reinhardt,et al. Comparative in vitro activities of selected antimicrobial agents against Aeromonas species and Plesiomonas shigelloides , 1985, Antimicrobial Agents and Chemotherapy.
[18] L. Peterson,et al. Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model. , 1986, The Journal of antimicrobial chemotherapy.
[19] H. Ingham,et al. TREATMENT OF SALMONELLA TYPHI CARRIER STATE WITH CIPROFLOXACIN , 1985, The Lancet.
[20] B. Azadian,et al. Two Neutropenic Patients with Multiple Resistant Pseudomonas Aeruginosa Septicaemia Treated with Ciprofloxacin , 1987, Journal of the Royal Society of Medicine.
[21] C. Ramírez-Ronda,et al. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections. , 1987, The American journal of medicine.
[22] H. Neu,et al. Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species. , 1987, Chemotherapy.
[23] R. N. Brogden,et al. Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. , 1985, Drugs.
[24] R. Goering,et al. Overview of preclinical studies with ciprofloxacin. , 1987, The American journal of medicine.
[25] F. Soriano,et al. Activity of nine antimicrobial agents against Corynebacterium group D2 strains isolated from clinical specimens and skin , 1987, Antimicrobial Agents and Chemotherapy.
[26] C. Bersani,et al. Effect of beta-lactam antibiotics on migration and bactericidal activity of human phagocytes , 1983, Antimicrobial Agents and Chemotherapy.
[27] I. Shalit,et al. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. , 1987, The American journal of medicine.
[28] G. Drusano,et al. Multiple‐dose ciprofloxacin dose ranging and kinetics , 1985, Clinical pharmacology and therapeutics.
[29] G. Drusano,et al. Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers , 1987, Antimicrobial Agents and Chemotherapy.
[30] B. Azadian,et al. Emergence of ciprofloxacin-resistant Pseudomonas aeruginosa after combined therapy with ciprofloxacin and amikacin. , 1986, The Journal of antimicrobial chemotherapy.
[31] T. Moreland,et al. Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis. , 1987, The Journal of antimicrobial chemotherapy.
[32] D. Dennig,et al. Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin. , 1987, Onkologie.
[33] A. Dalhoff,et al. Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration. , 1986, Chemotherapy.
[34] A. Staib,et al. Gyrase-inhibitors impair caffeine elimination in man. , 1987, Methods and findings in experimental and clinical pharmacology.
[35] R. Auckenthaler,et al. In-vitro activity of newer quinolones against aerobic bacteria. , 1986, The Journal of antimicrobial chemotherapy.
[36] A. Lesse,et al. Oral ciprofloxacin therapy for gram-negative bacillary osteomyelitis. , 1987, The American journal of medicine.
[37] R. Greenblatt,et al. Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. , 1987, The American journal of medicine.
[38] R. Maserati,et al. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis , 1985, Antimicrobial Agents and Chemotherapy.
[39] J. Righter. Ciprofloxacin treatment of Staphylococcus aureus infections. , 1987, The Journal of antimicrobial chemotherapy.
[40] M. McElrath,et al. The Pharmacokinetics and Serum and Urine Bactericidal Activity of Ciprofloxacin , 1985, Journal of clinical pharmacology.
[41] Y. Michel-Briand,et al. Elimination of plasmids from Enterobacteriaceae by 4-quinolone derivatives. , 1986, The Journal of antimicrobial chemotherapy.
[42] I. Casin,et al. In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi , 1986, Antimicrobial Agents and Chemotherapy.
[43] H. Neu. Ciprofloxacin: an overview and prospective appraisal. , 1987, The American journal of medicine.
[44] M. Bergeron,et al. Tissue penetration of ciprofloxacin after single and multiple doses , 1986, Antimicrobial Agents and Chemotherapy.
[45] R. Fass. Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections , 1987, Antimicrobial Agents and Chemotherapy.
[46] T. Bergan,et al. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora , 1986, Antimicrobial Agents and Chemotherapy.
[47] A. Forsgren,et al. 4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro , 1987, Antimicrobial Agents and Chemotherapy.
[48] J. Timm,et al. Low dose ciprofloxacin in respiratory tract infections a randomized comparison with doxycycline in general practice , 1987 .
[49] R. Auckenthaler,et al. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis , 1987, Antimicrobial Agents and Chemotherapy.
[50] J. Rahal,et al. Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci , 1986, Antimicrobial Agents and Chemotherapy.
[51] G. Bodey,et al. In vitro susceptibility of Acinetobacter species to various antimicrobial agents , 1986, Antimicrobial Agents and Chemotherapy.
[52] A. Wronski,et al. Ciprofloxacin in acute male gonorrhea. , 1986, Arzneimittel-Forschung.
[53] D. Reeves,et al. In-vitro studies with ciprofloxacin, a new 4-quinolone compound. , 1984, The Journal of antimicrobial chemotherapy.
[54] D. Badenoch,et al. Oral ciprofloxacin as prophylaxis for optical urethrotomy. , 1987, British journal of urology.
[55] W. Wilson,et al. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. , 1987, The American journal of medicine.
[56] M. Hodson,et al. CIPROFLOXACIN-RESISTANT PSEUDOMONAS , 1985, The Lancet.
[57] A. Forsgren,et al. Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth , 1987, Antimicrobial Agents and Chemotherapy.
[58] R. Wall,et al. The comparative in-vitro activity of twelve 4-quinolone antimicrobials against Haemophilus ducreyi. , 1985, The Journal of antimicrobial chemotherapy.
[59] D. Folta,et al. Comparative activity of ciprofloxacin and other new agents against 1454 clinical isolates at a community hospital , 1985 .
[60] H. Neu,et al. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria , 1984, Antimicrobial Agents and Chemotherapy.
[61] M. Flepp,et al. Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women , 1987, Antimicrobial Agents and Chemotherapy.
[62] P. Ruane,et al. Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. , 1987, The American journal of medicine.
[63] M. Bergeron,et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients , 1986, Antimicrobial Agents and Chemotherapy.
[64] R. Fass. In vitro activity of ciprofloxacin (Bay o 9867) , 1983, Antimicrobial Agents and Chemotherapy.
[65] B. Watt,et al. Is ciprofloxacin active against clinically important anaerobes? , 1986, The Journal of antimicrobial chemotherapy.
[66] G. Drusano. An overview of the pharmacology of intravenously administered ciprofloxacin. , 1987, The American journal of medicine.
[67] A. Bayer,et al. Pharmacokinetics of ciprofloxacin in the elderly. , 1987, Respiration; international review of thoracic diseases.
[68] R. Lowry,et al. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. , 1986, The Journal of antimicrobial chemotherapy.
[69] M. Leyland,et al. Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. , 1986, The Journal of antimicrobial chemotherapy.
[70] J. Crane,et al. Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. , 1986, The Journal of antimicrobial chemotherapy.
[71] S. Suerbaum,et al. Influence of beta-lactam antibiotics and ciprofloxacin on cell envelope of Escherichia coli , 1987, Antimicrobial Agents and Chemotherapy.
[72] I. Shalit,et al. In vitro antibacterial activities of antibiotics against Pseudomonas aeruginosa in peritoneal dialysis fluid , 1985, Antimicrobial Agents and Chemotherapy.
[73] E. Perea,et al. Activities of new quinoline derivatives against genital pathogens , 1985, Antimicrobial Agents and Chemotherapy.
[74] E. Perea,et al. Comparative clinical efficacy of two different single-dose ciprofloxacin treatments for uncomplicated gonorrhea. , 1986, Sexually transmitted diseases.
[75] R. Eng,et al. Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus , 1985, Antimicrobial Agents and Chemotherapy.
[76] A. Forsgren,et al. Effect of tetracycline on the phagocytic function of human leukocytes. , 1974, The Journal of infectious diseases.
[77] H. Young,et al. Ciprofloxacin versus ampicillin and probenecid in the treatment of uncomplicated gonorrhoea in men. , 1987, The Journal of antimicrobial chemotherapy.
[78] R. Goering,et al. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes , 1984, Antimicrobial Agents and Chemotherapy.
[79] A. Digranes. In vitro activity of amifloxacin (WIN 49,375) compared with those of ciprofloxacin and ofloxacin. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section B, Microbiology.
[80] S. Pattyn,et al. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives , 1984, Antimicrobial Agents and Chemotherapy.
[81] C. R. Smith,et al. The adverse effects of fluoroquinolones. , 1987, The Journal of antimicrobial chemotherapy.
[82] G. Drusano,et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers , 1985, Antimicrobial Agents and Chemotherapy.
[83] I. Fong,et al. Ciprofloxacin concentrations in bone and muscle after oral dosing , 1986, Antimicrobial Agents and Chemotherapy.
[84] P. Ball,et al. Ciprofloxacin: an overview of adverse experiences. , 1986, The Journal of antimicrobial chemotherapy.
[85] J. Ariza,et al. In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. , 1986, The Journal of antimicrobial chemotherapy.
[86] K. Yamaguchi,et al. The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. , 1986, The Journal of antimicrobial chemotherapy.
[87] B. O’Brien,et al. Ciprofloxacin: an update on clinical experience. , 1987, The American journal of medicine.
[88] 小林 宏行他. Comparative clinical study of ciprofloxacin and cefaclor in the treatment of respiratory tract infections. , 1986 .
[89] J. Hamilton-miller,et al. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers , 1984, Antimicrobial Agents and Chemotherapy.
[90] L. Sollenberger,et al. Susceptibility of non-fermentative gram-negative bacteria to ciprofloxacin, norfloxacin, amifloxacin, pefloxacin and cefpirome. , 1986, The Journal of antimicrobial chemotherapy.
[91] H. Lode,et al. Pharmacokinetics of ciprofloxacin after oral and parenteral administration , 1985, Antimicrobial Agents and Chemotherapy.
[92] D. Honeybourne,et al. CIPROFLOXACIN PENETRATION INTO LUNGS , 1987, The Lancet.
[93] J. Bosso,et al. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis. , 1987, The American journal of medicine.
[94] C. Hart,et al. Evaluation of ciprofloxacin 500 mg twice daily for one week in treating uncomplicated gonococcal chlamydial, and non-specific urethritis in men. , 1986, Genitourinary medicine.
[95] T. Bergan,et al. Tolerance of ciprofloxacin at injection site, systemic safety and effect on electroencephalogram. , 1987, Chemotherapy.
[96] J. Klastersky,et al. Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin , 1986, Antimicrobial Agents and Chemotherapy.
[97] C. Licitra,et al. Clinical efficacy and levels of ciprofloxacin in tissue in patients with soft tissue infection , 1987, Antimicrobial Agents and Chemotherapy.
[98] F. R. Venezio,et al. Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria , 1986, Antimicrobial Agents and Chemotherapy.
[99] H. Shwachman,et al. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period. , 1958, A.M.A. journal of diseases of children.
[100] A. Bayer,et al. Comparative efficacy of ciprofloxacin and ceftriaxone in experimental arthritis caused by Escherichia coli , 1986, Antimicrobial Agents and Chemotherapy.
[101] S. Esposito,et al. In vitro synergy of ciprofloxacin and three other antibiotics against Bacteroides fragilis. , 1987, Drugs under experimental and clinical research.
[102] G. Ridgway,et al. The Activity of Ciprofloxacin and Other 4-Quinolones Against Chlamydia trachomatis and Mycoplasmas In Vitro , 1986 .
[103] H. Neu,et al. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. , 1987, The American journal of medicine.
[104] A. Mazzone,et al. Ciprofloxacin concentrations in human fluids and tissues following a single oral dose. , 1987, International journal of clinical pharmacology research.
[105] D. Hooper,et al. Mechanisms of action of and resistance to ciprofloxacin. , 1987, The American journal of medicine.
[106] L. Eron,et al. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria , 1985, Antimicrobial Agents and Chemotherapy.
[107] K. Schmidt,et al. Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization. , 1987, Journal of chromatography.
[108] M. Rosseneu,et al. The pharmacokinetics of ciprofloxacin in patients with impaired renal function. , 1985, The Journal of antimicrobial chemotherapy.
[109] I. Fong,et al. Treatment of nongonococcal urethritis with ciprofloxacin. , 1987, The American journal of medicine.
[110] R. Rubin,et al. New approaches to the treatment of urinary tract infection. , 1987, The American journal of medicine.
[111] M. Sande,et al. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus , 1986, Antimicrobial Agents and Chemotherapy.
[112] D. Ilstrup,et al. Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women. , 1986, The Journal of antimicrobial chemotherapy.
[113] N. Høiby,et al. FREQUENT ANTIBIOTIC THERAPY IMPROVES SURVIVAL OF CYSTIC FIBROSIS PATIENTS WITH CHRONIC PSEUDOMONAS AERUGINOSA INFECTION , 1983 .
[114] C. Sanders,et al. Efficacy of ciprofloxacin in the treatment of nasopharyngeal carriers of Neisseria meningitidis. , 1987, The Journal of infectious diseases.
[115] G. Krol,et al. Liquid Chromatographic Analysis of Ciprofloxacin and Ciprofloxacin Metabolites in Body Fluids , 1986 .
[116] Jerome J. Schentag,et al. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. , 1987, The American journal of medicine.
[117] C Thornsberry,et al. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae , 1985, Antimicrobial Agents and Chemotherapy.
[118] M. Cynamon,et al. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare , 1986, Antimicrobial Agents and Chemotherapy.
[119] C. Mcnulty,et al. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents , 1985, Antimicrobial Agents and Chemotherapy.
[120] R. Stern,et al. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis. , 1987, The American journal of medicine.
[121] H. Humphreys,et al. CIPROFLOXACIN-RESISTANT STAPHYLOCOCCUS AUREUS , 1985, The Lancet.
[122] R. Greenwood,et al. Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis , 1986, Antimicrobial Agents and Chemotherapy.
[123] R. Echols,et al. Effect of peritoneal dialysis fluid and pH on bactericidal activity of ciprofloxacin , 1987, Antimicrobial Agents and Chemotherapy.
[124] L. Preheim,et al. CIPROFLOXACIN AND ANTACIDS , 1986, The Lancet.
[125] M. Rozenberg-Arska,et al. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. , 1985, The Journal of infectious diseases.
[126] M. Stieglitz,et al. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants. , 1985, Chemotherapy.
[127] G. Eliopoulos,et al. InVitro Activity OfCiprofloxacin, aNewCarboxyquinoline Antimicrobial Agent , 1984 .
[128] S. Gollapudi,et al. Effect of ciprofloxacin on mitogen-stimulated lymphocyte proliferation , 1986, Antimicrobial Agents and Chemotherapy.
[129] M. Leyland,et al. Multiply resistant Salmonella typhimurium septicaemia in an immunocompromised patient successfully treated with ciprofloxacin. , 1985, The Journal of antimicrobial chemotherapy.
[130] C. Norden,et al. In vitro activity of ciprofloxacin against aerobic gram-negative bacteria , 1984, Antimicrobial Agents and Chemotherapy.
[131] S. Raoof,et al. Ciprofloxacin increases serum levels of theophylline. , 1987, The American journal of medicine.
[132] H. Pichler,et al. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. , 1987, The American journal of medicine.
[133] E. Hvidberg,et al. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients. , 1987, The Journal of antimicrobial chemotherapy.
[134] J. Selkon,et al. CLINICAL RESISTANCE TO LONG-TERM ORAL CIPROFLOXACIN , 1985, The Lancet.
[135] I. Nilsson-ehle. Assay of ciprofloxacin and norfloxacin in serum and urine by high-performance liquid chromatography. , 1987, Journal of chromatography.
[136] J. Klastersky,et al. Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis. , 1985, The Journal of antimicrobial chemotherapy.
[137] M. Delmée,et al. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile , 1986, Antimicrobial Agents and Chemotherapy.
[138] M. Bergeron,et al. Pharmacokinetics of Ciprofloxacin in Elderly Subjects , 1986, Pharmacotherapy.
[139] J. Cohen,et al. ANTIBIOTIC-INDUCED ENDOTOXIN RELEASE , 1985, The Lancet.
[140] D. Gilbert,et al. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. , 1987, The American journal of medicine.
[141] G. Drusano,et al. Effect of dose size on bioavailability of ciprofloxacin , 1987, Antimicrobial Agents and Chemotherapy.
[142] R. Fass. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. , 1987, The American journal of medicine.
[143] R. Fass. Treatment of skin and soft tissue infections with oral ciprofloxacin. , 1986, The Journal of antimicrobial chemotherapy.
[144] H. Muytjens,et al. Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections. , 1985, The Journal of antimicrobial chemotherapy.
[145] L. Ayers,et al. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid , 1984, Antimicrobial Agents and Chemotherapy.
[146] U. Petersen,et al. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. , 1987, Arzneimittel-Forschung.
[147] J. Crane,et al. Uptake of ciprofloxacin by human neutrophils. , 1985, The Journal of antimicrobial chemotherapy.
[148] M. Bergeron,et al. Determination of ciprofloxacin in biological samples by reversed-phase high performance liquid chromatography. , 1986, Therapeutic drug monitoring.
[149] G. Drusano,et al. Absolute oral bioavailability of ciprofloxacin , 1986, Antimicrobial Agents and Chemotherapy.
[150] S. T. Pottratz,et al. Multiple‐dose ciprofloxacin kinetics in normal subjects , 1984, Clinical pharmacology and therapeutics.
[151] B. Joos,et al. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin , 1985, Antimicrobial Agents and Chemotherapy.
[152] C. Collins,et al. In-vitro susceptibility of mycobacteria to ciprofloxacin. , 1985, The Journal of antimicrobial chemotherapy.
[153] A. Sivonen,et al. Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland , 1987, Antimicrobial Agents and Chemotherapy.
[154] R. Petrak,et al. Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species , 1985, Antimicrobial Agents and Chemotherapy.
[155] L. Bush,et al. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. , 1987, The American journal of medicine.
[156] C. Bijleveld,et al. CIPROFLOXACIN FOR CHOLANGITIS AFTER HEPATIC PORTOENTEROSTOMY , 1987, The Lancet.
[157] M. Wood,et al. Ciprofloxacin for soft tissue infections. , 1986, The Journal of antimicrobial chemotherapy.
[158] H. Van Poppel,et al. Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin. , 1986, Chemotherapy.
[159] J. Domagala,et al. New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. , 1986, Journal of medicinal chemistry.
[160] R. J. Butland,et al. ORAL CIPROFLOXACIN COMPARED WITH CONVENTIONAL INTRAVENOUS TREATMENT FOR PSEUDOMONAS AERUGINOSA INFECTION IN ADULTS WITH CYSTIC FIBROSIS , 1987, The Lancet.
[161] R. Prabhala,et al. In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867) , 1984, Antimicrobial Agents and Chemotherapy.
[162] J. Smith. The mode of action of 4-quinolones and possible mechanisms of resistance. , 1986, The Journal of antimicrobial chemotherapy.
[163] F. Debruyne,et al. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration. , 1985, Chemotherapy.
[164] D. Badenoch,et al. Oral ciprofloxacin as prophylaxis in transurethral resection of the prostate. , 1987, British journal of urology.
[165] M. Leyland,et al. CIPROFLOXACIN-RESISTANT STAPHYLOCOCCI , 1985, The Lancet.
[166] N. Legakis,et al. In-vitro activity of ciprofloxacin against clinical isolates of mycobacteria resistant to antimycobacterial drugs. , 1985, The Journal of antimicrobial chemotherapy.
[167] K. Fuursted. Post-antibiotic effect and killing activity of ciprofloxacin against Staphylococcus aureus. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section B, Microbiology.
[168] J. Cohen,et al. In-vitro study of the activity of ciprofloxacin alone and in combination against strains of Pseudomonas aeruginosa with multiple antibiotic resistance. , 1986, The Journal of antimicrobial chemotherapy.
[169] A. Dalhoff,et al. Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. , 1987, The American journal of medicine.
[170] H. Stutman. Summary of a workshop on ciprofloxacin use in patients with cystic fibrosis , 1987 .
[171] E. Rodriguez-Noriega,et al. Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections. , 1987, American Journal of Medicine.
[172] M. Dudley,et al. Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin , 1986, Antimicrobial Agents and Chemotherapy.
[173] V. Sutter,et al. Comparative activity of ciprofloxacin against anaerobic bacteria , 1985, Antimicrobial Agents and Chemotherapy.
[174] C. Easmon,et al. Ciprofloxacin treatment of systemic salmonella infection in sensitive and resistance mice. , 1985, The Journal of antimicrobial chemotherapy.
[175] R. Spencer,et al. Comparative in-vitro activity of five fluoroquinolones against mycobacteria. , 1987, The Journal of antimicrobial chemotherapy.
[176] A. P. Ball,et al. Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. , 1986, The Journal of antimicrobial chemotherapy.
[177] G. Pankey,et al. Ciprofloxacin in the treatment of bacterial skin infections , 1987 .
[178] I. Phillips,et al. Ciprofloxacin for treating urethral gonorrhoea in men. , 1986, Genitourinary medicine.
[179] L. Peterson,et al. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods. , 1987, The American journal of medicine.
[180] T. Mulvihill,et al. The in-vitro activity of some antimicrobial agents against methicillin-resistant Staphylococcus aureus. , 1985, The Journal of antimicrobial chemotherapy.
[181] A. Newland,et al. Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients. , 1986, The Journal of antimicrobial chemotherapy.
[182] H. Muytjens,et al. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid , 1983, Antimicrobial Agents and Chemotherapy.
[183] T. Bergan,et al. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses. , 1987, The American journal of medicine.
[184] H. Neu,et al. The post-antimicrobial suppressive effect of quinolone agents. , 1987, Drugs under experimental and clinical research.
[185] A. Forsgren. Comparative in vitro Activity of Three New Quinolone Antibiotics against Recent Clinical Isolates , 1985 .
[186] G. Cornaglia,et al. In vitro activity of ciprofloxacin against aerobic bacteria isolated in a southern European hospital , 1987, Antimicrobial Agents and Chemotherapy.
[187] R. Greenwood,et al. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. , 1987, The American journal of medicine.
[188] T. Golper,et al. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis , 1987, Antimicrobial Agents and Chemotherapy.
[189] C. Perronne,et al. Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination , 1987, Antimicrobial Agents and Chemotherapy.
[190] H. Lode,et al. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections , 1987, Antimicrobial Agents and Chemotherapy.
[191] A. Smith,et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis , 1987, Antimicrobial Agents and Chemotherapy.
[192] C. Stratton,et al. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies , 1987, Antimicrobial Agents and Chemotherapy.
[193] G. Ridgway,et al. Comparative in vitro studies with 4-quinolone antimicrobials. , 1985, Drugs under experimental and clinical research.
[194] H. Handsfield,et al. Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men , 1986, Antimicrobial Agents and Chemotherapy.
[195] B. Angelucci,et al. Oral ciprofloxacin in the treatment of uncomplicated gonococcal urethritis in men. , 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.
[196] B. Régnier,et al. Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis , 1987, Antimicrobial Agents and Chemotherapy.
[197] D. Waaij,et al. Colonization resistance of the digestive tract: clinical consequences and implications , 1982 .
[198] G. Ridgway,et al. Single dose ciprofloxacin for treating gonococcal infections in men. , 1985, Genitourinary medicine.
[199] C. Norden,et al. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. , 1985, The Journal of infectious diseases.
[200] M. Zweerink,et al. Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids , 1986, Antimicrobial Agents and Chemotherapy.
[201] U. Ullmann,et al. Influence of various antimicrobial agents on the chemiluminescence of phagocytosing human granulocytes. , 1986, Chemotherapy.
[202] V. Labombardi,et al. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. , 1987, The American journal of medicine.
[203] A. Digranes,et al. In vitro activities of ciprofloxacin, ofloxacin, norfloxacin and rosoxacin compared with cinoxacin and trimethoprim. , 1985, Chemotherapy.
[204] D. Reeves,et al. RESISTANCE TO CIPROFLOXACIN , 1985, The Lancet.
[205] J. Pennington,et al. Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia , 1984, Antimicrobial Agents and Chemotherapy.
[206] H. Giamarellou,et al. Use of intravenous ciprofloxacin in difficult-to-treat infections. , 1987, The American journal of medicine.
[207] P. Piot,et al. Antimicrobial susceptibility and characterization of outer membrane proteins of Haemophilus ducreyi isolated in Thailand , 1985, Journal of clinical microbiology.
[208] H. Dupont,et al. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial. , 1987, Annals of internal medicine.
[209] A. Bayer,et al. Efficacy of ciprofloxacin in experimental arthritis caused by Escherichia coli--in vitro-in vivo correlations. , 1985, The Journal of infectious diseases.
[210] G. Lindsay,et al. Penetration of ciprofloxacin into aqueous humor. , 1986, Transactions of the ophthalmological societies of the United Kingdom.
[211] L. Parish,et al. Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime. , 1987, The American journal of medicine.